In breast cancer, TGF-β1 activates a Smad protein-linked pathway, resulting in EMT phenotype and lymphatic migration in response to CCL21 release from lymphatic endothelial cells and chemotaxis of CCR7-expressing breast cancer cells [303]. Here, CCL21 is linked to breast cancer.